Business

VOLUNTARY ANNOUNCEMENT A PHASE III CLINICAL TRIAL OF LP-003 FOR THE INDICATION OF SEASONAL AR MET PRIMARY ENDPOINTS

VOLUNTARY ANNOUNCEMENT A PHASE III CLINICAL TRIAL OF LP-003 FOR THE INDICATION OF SEASONAL AR MET PRIMARY ENDPOINTS

Longbio Pharma (suzhou) Co., Ltd. Class HJune 11, 20263

VOLUNTARY ANNOUNCEMENT A PHASE III CLINICAL TRIAL OF LP-003 FOR THE INDICATION OF SEASONAL AR MET PRIMARY ENDPOINTS

About this update from Longbio Pharma (suzhou) Co., Ltd. Class H

Longbio Pharma (suzhou) Co., Ltd. Class H (1779) Press Release View Attachment

View stock analysis, news, and events for Longbio Pharma (suzhou) Co., Ltd. Class H

More from Longbio Pharma (suzhou) Co., Ltd. Class H

Altruist Biologics Congratulates Partner LongBio Pharma on the BLA Acceptance of LP-003 by the China NMPA

September 14, 2026

All Longbio Pharma (suzhou) Co., Ltd. Class H news →